UNSPSC 51313438: Pheniramine maleate

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NYW905655B. European Medicines Agency schedules Pheniramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03747MIG. Pheniramine maleate generally arises in the molecular formula C20H24N2O4. The term 'pheniramine maleate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule pheniramine maleate under HS 29333999 and SITC 51574.

As of Q4 2014, PHENIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Pheniramine maleate bears US NLM identifiers UMLS ID C0887016 and NCI Concept Code C29358. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313438 Pheniramine maleate is a Commodity code nominally identifying a single antihistamine product, but recent state and local solicitations tagged under this code show minimal alignment with the specific pharmaceutical listed. The actual work being procured under the code spans generic multi-source pharmaceuticals, over-the-counter products, naloxone, and pharmacy benefit program management—indicating that state and local procurement systems are using this code as a broad pharmaceutical catch-all rather than to identify pheniramine maleate specifically. Issuing bodies include state health and human services departments, county public health authorities, and cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission represent the most prominent recent activity, with county-level procurement appearing through Seminole County, Florida.

Recent opportunities span three distinct procurement strategies. The Minnesota MMCAP issued an RFP on January 20, 2026 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Texas HHS issued a Request for Information in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity outside traditional pharmacy benefit manager and wholesaler arrangements. Seminole County, Florida posted an IFB on June 30, 2026 due July 26, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, potentially funded through FEMA. Activity concentrates in the upper South and Upper Midwest, with Texas and Florida showing current procurement momentum alongside the multi-state Minnesota cooperative.